RRS HA Long Lasting Secured Best Injectable in Skin Revitalization at AMWC 2026, strengthening Skin Tech Pharma Group leadership in the Skin Builder category
Published: 02 Jul 2026
Author: Towards Healthcare
Skin Tech Pharma Group is pleased to announce that its flagship injectable, RRS® HA LONG LASTING, has been awarded as Best Injectable in the Skin Revitalization category at the AMWC Aesthetic Medicine Awards 2026, one of the esteemed recognitions in aesthetic medicine.
Moreover, this award admits the product's contribution to expanding regenerative aesthetic medicine & highlights rising demand for treatment solutions that transfer natural outcomes, assisting long-term skin health, tissue quality, & dignified ageing.
Márcio Rodrigues, CEO of Skin Tech Pharma Group, stated that this award is a prominent step for them & a testament to empower their long-term strategy. This framework is continuing the development, coupled with scientific comprehensiveness, distinguished innovation, & a deep understanding of healthcare professionals' requirements.
About Skin Tech Pharma Group
It is a global firm in aesthetic medicine that produces high-quality CE-marked medical devices & sophisticated cosmeceuticals. The Skin Tech Pharma Group was founded in 1994 by Dr. Philippe Deprez & now advancing its 30 years of innovation by operating a state-of-the-art in-house laboratory with the worldwide R&D team.
About RRS® HA Long Lasting
Primarily, it is a cross-linked hyaluronic acid skin builder that is integrated with a protective buffer of 15 amino acids to spur dermal structure. This further improves hydration, firmness, and texture while offering a clear lifting effect & optimizing wrinkles and fine lines.
According to Towards Healthcare, the Europe bioregenerative aesthetic injectable market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 1.24 billion in 2026 to approximately USD 3.83 billion by 2035, representing a compound annual growth rate (CAGR) of 13.4% from 2026 to 2035. Key catalysts are a massive rise in the geriatric population, a highly increasing consumer preference for minimally invasive, natural-looking ‘preventative’ anti-ageing treatments, & stricter EU Medical Device Regulation (MDR).
Continuous Expansion of Body Indications & Growth of Biostimulators
According to Towards Healthcare, the Europe bioregenerative aesthetic injectable market has been widening body applications, like PLLA-based injectables, which are initiating notable new pathways for gluteal, thigh, & décolletage rejuvenation. Apart from this, to meet the rising demand for regenerative materials that boost skin quality & stimulate native collagen production, Calcium hydroxylapatite (CaHA) & polynucleotides (PDRN) are advancing the charge for repairing & revitalizing aging skin tissues.